PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33191863-0 2020 Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-kappaB signal pathway. Bortezomib 54-64 mechanistic target of rapamycin kinase Homo sapiens 109-113 33938943-9 2021 G9a/GLP targeting sensitizes MM cells to the proteasome inhibitors (PIs) bortezomib and carfilzomib, by (further) reducing mTOR signaling and c-MYC levels and activating p-38 and SAPK/JNK signaling. Bortezomib 73-83 mechanistic target of rapamycin kinase Homo sapiens 123-127 33564319-7 2021 The efficacy of combining bortezomib and E35 was investigated by examining the expression of the Akt/mTOR/4EBP1 signaling pathway-related proteins. Bortezomib 26-36 mechanistic target of rapamycin kinase Homo sapiens 101-105 33289516-0 2021 Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-kappaB/TNF-alpha/Akt/mTOR/P70S6K/Smurf2 pathway via IkappaBalpha protein stabilization. Bortezomib 0-10 mechanistic target of rapamycin kinase Homo sapiens 94-98 33289516-7 2021 In addition to blocking Akt/mammalian target of rapamycin (mTOR)/p70S6 kinase/Smurf2 signaling, bortezomib"s effect on the epithelial-mesenchymal transition was associated with inhibition of nuclear factor kappa B (NF-kappaB) pathway by stabilizing inhibitor of NF-kappaB. Bortezomib 96-106 mechanistic target of rapamycin kinase Homo sapiens 28-57 33289516-7 2021 In addition to blocking Akt/mammalian target of rapamycin (mTOR)/p70S6 kinase/Smurf2 signaling, bortezomib"s effect on the epithelial-mesenchymal transition was associated with inhibition of nuclear factor kappa B (NF-kappaB) pathway by stabilizing inhibitor of NF-kappaB. Bortezomib 96-106 mechanistic target of rapamycin kinase Homo sapiens 59-63 33191863-11 2020 In addition, the bortezomib-induced cytotoxicity on MM cells was significantly augmented by VU0359595 through efficient suppression of the mTOR/NF-kappaB signal pathway. Bortezomib 17-27 mechanistic target of rapamycin kinase Homo sapiens 139-143 29057477-5 2018 Moreover, combination treatment with MIP-1alpha neutralizing antibody and melphalan or bortezomib inhibited extracellular signal regulated kinase 1/2 (ERK1/2), Akt, and mammalian target of rapamycin (mTOR) activation, Bcl-2, Bcl-xL, and Survivin expression, and upregulated the expression of Bim and cleaved Poly (ADP-ribose) polymerase (PARP). Bortezomib 87-97 mechanistic target of rapamycin kinase Homo sapiens 169-198 29997148-0 2019 Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. Bortezomib 54-64 mechanistic target of rapamycin kinase Homo sapiens 77-81 32126150-0 2020 Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway. Bortezomib 59-69 mechanistic target of rapamycin kinase Homo sapiens 104-108 31140729-0 2019 Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-alpha-Smurf1-Akt-mTOR-P70S6K pathway. Bortezomib 0-10 mechanistic target of rapamycin kinase Homo sapiens 131-135 29057477-5 2018 Moreover, combination treatment with MIP-1alpha neutralizing antibody and melphalan or bortezomib inhibited extracellular signal regulated kinase 1/2 (ERK1/2), Akt, and mammalian target of rapamycin (mTOR) activation, Bcl-2, Bcl-xL, and Survivin expression, and upregulated the expression of Bim and cleaved Poly (ADP-ribose) polymerase (PARP). Bortezomib 87-97 mechanistic target of rapamycin kinase Homo sapiens 200-204 28899456-9 2018 Finally, BZ induced dephosphorylation of AKT and mTOR, which was significantly attenuated by ClC5 inhibition. Bortezomib 9-11 mechanistic target of rapamycin kinase Homo sapiens 49-53 29755672-9 2018 PP242 exhibited a synergistic effect with lenalidomide and bortezomib, suggesting that mTOR inhibition can enhance the anti-angiogenic effect of these drugs. Bortezomib 59-69 mechanistic target of rapamycin kinase Homo sapiens 87-91 28899456-10 2018 However, ClC5 upregulation further enhanced AKT and mTOR dephosphorylation induced by BZ. Bortezomib 86-88 mechanistic target of rapamycin kinase Homo sapiens 52-56 28696812-2 2018 Combined proteasome and mTOR inhibition, demonstrated with bortezomib and everolimus in a preclinical model, thus warrants evaluation in humans. Bortezomib 59-69 mechanistic target of rapamycin kinase Homo sapiens 24-28 29482577-15 2018 CONCLUSIONS: Our findings demonstrated that increased thioredoxin plays a critical role in bortezomib resistance in multiple myeloma through mitophagy inactivation and increased mTOR and ERK1/2 phosphorylation. Bortezomib 91-101 mechanistic target of rapamycin kinase Homo sapiens 178-182 29996117-0 2018 Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib. Bortezomib 102-112 mechanistic target of rapamycin kinase Homo sapiens 9-38 29996117-0 2018 Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib. Bortezomib 102-112 mechanistic target of rapamycin kinase Homo sapiens 40-44 29996117-4 2018 The purposes of this study were to examine 1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical pain and cold hypersensitivity evoked by BTZ and 2) the underlying mechanisms responsible for the role of mTOR in regulating BTZ-induced neuropathic pain. Bortezomib 162-165 mechanistic target of rapamycin kinase Homo sapiens 70-99 29996117-4 2018 The purposes of this study were to examine 1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical pain and cold hypersensitivity evoked by BTZ and 2) the underlying mechanisms responsible for the role of mTOR in regulating BTZ-induced neuropathic pain. Bortezomib 162-165 mechanistic target of rapamycin kinase Homo sapiens 101-105 29996117-4 2018 The purposes of this study were to examine 1) the effects of blocking mammalian target of rapamycin (mTOR) on mechanical pain and cold hypersensitivity evoked by BTZ and 2) the underlying mechanisms responsible for the role of mTOR in regulating BTZ-induced neuropathic pain. Bortezomib 246-249 mechanistic target of rapamycin kinase Homo sapiens 227-231 23916134-0 2013 Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation. Bortezomib 15-25 mechanistic target of rapamycin kinase Homo sapiens 34-38 25530422-7 2015 Although Bortezomib increased the levels of p53 and increased the expression of pro-apoptotic target genes in ERalpha+ breast cancer cells harboring wild-type p53, Bortezomib also exerts anti-tumoral effects on ERalpha+ breast cancer cells through suppression of ERalpha expression and inhibition of PI3K/Akt/mammalian target of rapamycin (mTOR) and ERK signaling independently of functional p53. Bortezomib 164-174 mechanistic target of rapamycin kinase Homo sapiens 309-338 25530422-7 2015 Although Bortezomib increased the levels of p53 and increased the expression of pro-apoptotic target genes in ERalpha+ breast cancer cells harboring wild-type p53, Bortezomib also exerts anti-tumoral effects on ERalpha+ breast cancer cells through suppression of ERalpha expression and inhibition of PI3K/Akt/mammalian target of rapamycin (mTOR) and ERK signaling independently of functional p53. Bortezomib 164-174 mechanistic target of rapamycin kinase Homo sapiens 340-344 28549771-0 2017 Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study. Bortezomib 78-88 mechanistic target of rapamycin kinase Homo sapiens 16-20 26194835-6 2015 Western blotting assays presented bortezomib could suppress the phosphorylation of Akt and mTOR, and down-regulate the expression of MMP2 and MMP9. Bortezomib 34-44 mechanistic target of rapamycin kinase Homo sapiens 91-95 26194835-7 2015 CONCLUSIONS: These results suggested bortezomib could inhibit migration and invasion in cervical carcinoma HeLa cell, which might be related to Akt/mTOR signal pathway. Bortezomib 37-47 mechanistic target of rapamycin kinase Homo sapiens 148-152 22560334-0 2012 The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Bortezomib 95-105 mechanistic target of rapamycin kinase Homo sapiens 18-22 26824026-14 2013 We propose that translational load does not contribute to bortezomib-induced death, but rather mTOR targeting may be successful in bortezomib resistant patients, stratified for eIF4E/4EBPs. Bortezomib 131-141 mechanistic target of rapamycin kinase Homo sapiens 95-99 22560334-6 2012 We also generated bortezomib-resistant MCL cell lines and found increased phosphorylation of Akt and mTOR. Bortezomib 18-28 mechanistic target of rapamycin kinase Homo sapiens 101-105 22339676-0 2012 Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Bortezomib 43-53 mechanistic target of rapamycin kinase Homo sapiens 110-114 22313636-5 2012 Phosphorylation of AKT and its upstream regulator mTOR were reduced by bortezomib treatment in medulloblastoma cells. Bortezomib 71-81 mechanistic target of rapamycin kinase Homo sapiens 50-54 22339676-9 2012 Moreover, the Akt/mTOR activity in U266 cells treated with bortezomib was downregulated upon c-Met knockdown and c-Met knockdown U266 cells recovered chemoresistance upon the overexpression of Akt and mTOR. Bortezomib 59-69 mechanistic target of rapamycin kinase Homo sapiens 18-22 22339676-9 2012 Moreover, the Akt/mTOR activity in U266 cells treated with bortezomib was downregulated upon c-Met knockdown and c-Met knockdown U266 cells recovered chemoresistance upon the overexpression of Akt and mTOR. Bortezomib 59-69 mechanistic target of rapamycin kinase Homo sapiens 201-205 20100206-6 2010 Together, these results identify a possible novel mechanism of bortezomib resistance in myeloma patients mediated by REDD1 overexpression involving inhibition of mTORC1 activity and suggest that the use of mammalian target of rapamycin inhibitors in myeloma patients could be deleterious. Bortezomib 63-73 mechanistic target of rapamycin kinase Homo sapiens 206-235 21909688-10 2012 Taken together, these results suggest that bortezomib inhibits HIF-1alpha protein synthesis and its nuclear targeting through suppression of PI3K/Akt/mTOR and MAPK pathways, respectively, in both AD and AI PCa cells. Bortezomib 43-53 mechanistic target of rapamycin kinase Homo sapiens 150-154